Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit: 2010-2024

Historic Gross Profit for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$2.0 million.

  • China Pharma Holdings' Gross Profit rose 88.52% to -$59,654 in Q3 2025 from the same period last year, while for Sep 2025 it was -$443,314, marking a year-over-year increase of 76.72%. This contributed to the annual value of -$2.0 million for FY2024, which is 606.42% down from last year.
  • Per China Pharma Holdings' latest filing, its Gross Profit stood at -$2.0 million for FY2024, which was down 606.42% from -$281,085 recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Gross Profit registered a high of $2.0 million during FY2020, and its lowest value of -$2.0 million during FY2024.
  • Over the past 3 years, China Pharma Holdings' median Gross Profit value was -$493,916 (recorded in 2022), while the average stood at -$920,216.
  • In the last 5 years, China Pharma Holdings' Gross Profit surged by 43.09% in 2023 and then plummeted by 606.42% in 2024.
  • Over the past 5 years, China Pharma Holdings' Gross Profit (MRY) stood at $2.0 million in 2020, then plummeted by 82.12% to $349,270 in 2021, then plummeted by 241.41% to -$493,916 in 2022, then surged by 43.09% to -$281,085 in 2023, then plummeted by 606.42% to -$2.0 million in 2024.
  • Its Gross Profit was -$2.0 million in FY2024, compared to -$281,085 in FY2023 and -$493,916 in FY2022.